CLDN10 associated with immune infiltration is a novel progn…

Abstract

Aims: To identify the clinical roles of CLDN10 in clear cell renal cell carcinoma (ccRCC). Materials & methods: Using data from TCGA-KIRC, GEO DataSets and laboratory experiments to determine the prognostic and clinicopathological characteristics of CLDN10. Results: CLDN10 expression was remarkably reduced in ccRCC. Downregulated CLDN10 was related to metastasis and poor prognosis. Multivariate Cox analysis determined that elevated CLDN10 expression was independently correlated with longer OS and DFS. Moreover, CLDN10 expression was negatively associated with the methylation levels of cg10305311 and cg16275739. CLDN10 expression was also associated with naive CD4 and memory T-cell and dendritic cell infiltration. Conclusions: Immune-related CLDN10 is an independent prognostic biomarker of ccRCC. DNA hypermethylation plays an important role in decreased CLDN10 expression.

Keywords

CLDN10 DNA methylation ccRCC prognosis tumor immune cells

Authors & Affiliations

7 authors, click to expand affiliations / ORCID

Yang Wuping ORCID

Department of Urology, Peking University First Hospital, Beijing 100034, P.R. China. | Hereditary Kidney Cancer Research Center, Peking University First Hospital, Beijing 100034, P.R. China. | Institute of Urology, Peking University, Beijing 100034, P.R. China. | National Urological Cancer Center, Beijing 100034, P.R. China.

Li Lei

Department of Urology, Peking University First Hospital, Beijing 100034, P.R. China. | Hereditary Kidney Cancer Research Center, Peking University First Hospital, Beijing 100034, P.R. China. | Institute of Urology, Peking University, Beijing 100034, P.R. China. | National Urological Cancer Center, Beijing 100034, P.R. China.

Zhang Kenan

Department of Urology, Peking University First Hospital, Beijing 100034, P.R. China. | Hereditary Kidney Cancer Research Center, Peking University First Hospital, Beijing 100034, P.R. China. | Institute of Urology, Peking University, Beijing 100034, P.R. China. | National Urological Cancer Center, Beijing 100034, P.R. China.

Ma Kaifang

Department of Urology, Peking University First Hospital, Beijing 100034, P.R. China. | Hereditary Kidney Cancer Research Center, Peking University First Hospital, Beijing 100034, P.R. China. | Institute of Urology, Peking University, Beijing 100034, P.R. China. | National Urological Cancer Center, Beijing 100034, P.R. China.

Gong Yanqing

Department of Urology, Peking University First Hospital, Beijing 100034, P.R. China. | Hereditary Kidney Cancer Research Center, Peking University First Hospital, Beijing 100034, P.R. China. | Institute of Urology, Peking University, Beijing 100034, P.R. China. | National Urological Cancer Center, Beijing 100034, P.R. China.

Zhou Jingcheng

Department of Urology, Peking University First Hospital, Beijing 100034, P.R. China. | Hereditary Kidney Cancer Research Center, Peking University First Hospital, Beijing 100034, P.R. China. | Institute of Urology, Peking University, Beijing 100034, P.R. China. | National Urological Cancer Center, Beijing 100034, P.R. China.

Gong Kan ORCID

Department of Urology, Peking University First Hospital, Beijing 100034, P.R. China. | Hereditary Kidney Cancer Research Center, Peking University First Hospital, Beijing 100034, P.R. China. | Institute of Urology, Peking University, Beijing 100034, P.R. China. | National Urological Cancer Center, Beijing 100034, P.R. China.

CLDN10 associated with immune infiltration is a novel prognostic biomarker for clear cell renal cell carcinoma.

Contact

WeChat Official Account